A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis

Phase 2CompletedNCT01629420

Kissei Pharmaceutical Co., Ltd.20 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Endometriosis

Interventions

KLH-2109DRUG

Eligibility

Sex: FEMALEMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female patients with endometriosis Exclusion Criteria: * Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Locations (1)

Japan

Tokyo and Other Japanese City, Japan

Outcomes

Primary Outcomes

The severity score of the pelvic pain

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.